아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexamethasone krka tafla 4 mg
krka, d.d., novo mesto - dexamethasonum fosfat - tafla - 4 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexamethasone hameln stungulyf, lausn 4 mg/ml
hameln pharma gmbh - dexamethasonum natríumfosfat - stungulyf, lausn - 4 mg/ml
유럽 연합 -
아이슬란드어 -
EMA (European Medicines Agency)
kyprolis
amgen europe b.v. - carfilzomib - mergæxli - Æxlishemjandi lyf - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexaject stungulyf, lausn 2 mg/ml
dopharma research b.v.* - dexamethasonum natríumfosfat - stungulyf, lausn - 2 mg/ml
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexametason abcur tafla 1 mg
abcur ab - dexamethasonum fosfat - tafla - 1 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexametason abcur tafla 4 mg
abcur ab - dexamethasonum fosfat - tafla - 4 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexavit stungulyf/innrennslislyf, lausn 4 mg/ml
vital pharma nordic aps - dexamethasonum natríumfosfat - stungulyf/innrennslislyf, lausn - 4 mg/ml
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
maxidex augndropar, dreifa 1 mg/ml
novartis healthcare a/s - dexamethasonum fosfat - augndropar, dreifa - 1 mg/ml
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
opnol augndropar, lausn 1 mg/ml
karo pharma ab* - dexamethasonum fosfat - augndropar, lausn - 1 mg/ml
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
tobradex augndropar, dreifa
novartis healthcare a/s - dexamethasonum fosfat; tobramycinum inn - augndropar, dreifa